AKBA - Akebia Therapeutics Inc Revenue Breakdown

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: AMGN REGN VRTX BIIB GILD INCY ALKS NBIX AMRN EXEL

| Held by: VTI XBI IWM VXF IWN SCHA VTWO FESM VHT IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.02	Insider Own	3.50%	Shs Outstand	265.42M	Perf Week	0.71%
Market Cap	380.39M	Forward P/E	-	EPS next Y	-0.17	Insider Trans	-5.81%	Shs Float	258.52M	Perf Month	5.97%
Enterprise Value	410.15M	PEG	-	EPS next Q	-0.03	Inst Own	45.66%	Short Float	10.57%	Perf Quarter	-5.96%
Income	-5.34M	P/S	1.61	EPS this Y	-200.00%	Inst Trans	-1.94%	Short Ratio	9.08	Perf Half Y	-53.14%
Sales	236.20M	P/B	11.56	EPS next Y	-190.00%	ROA	-1.79%	Short Interest	27.31M	Perf YTD	-11.80%
Book/sh	0.12	P/C	2.04	EPS next 5Y	-	ROE	-	52W High	4.08 -65.18%	Perf Year	-41.56%
Cash/sh	0.70	P/FCF	5.62	EPS past 3/5Y	65.70% 62.40%	ROIC	-2.56%	52W Low	1.14 24.56%	Perf 3Y	56.30%
Dividend Est.	-	EV/EBITDA	16.56	Sales past 3/5Y	-6.88% -4.37%	Gross Margin	82.76%	Volatility	3.95% 5.30%	Perf 5Y	-55.63%
Dividend TTM	-	EV/Sales	1.74	EPS Y/Y TTM	94.76%	Oper. Margin	9.95%	ATR (14)	0.08	Perf 10Y	-84.91%
Dividend Ex-Date	-	Quick Ratio	1.46	Sales Y/Y TTM	47.46%	Profit Margin	-2.26%	RSI (14)	50.86	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.55	EPS Q/Q	55.80%	SMA20	-0.05%	Beta	0.38	Target Price	4.40
Payout	-	Debt/Eq	6.63	Sales Q/Q	23.93%	SMA50	4.25%	Rel Volume	0.51	Prev Close	1.42
Employees	194	LT Debt/Eq	5.40	Earnings	Feb 26 BMO	SMA200	-33.60%	Avg Volume	3.01M	Price	1.42
IPO	Mar 20, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-38.89% 25.01%	Trades		Volume	1,534,137	Change	0.00%

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)